Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8825236 | Radiology Case Reports | 2018 | 4 Pages |
Abstract
Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use, has been frequently reported. We report a case of ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum, identified using 3D fluid-attenuated inversion recovery.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Fumine MD, Ryota MD, Masayuki MD, PhD, Maki MD, PhD, Yasuo MD, Atsuro MD, Hajime MD, PhD,